



Dr Adrian Attard Trevisan, clarification

Perth, Australia & Malta – 28 March 2019 – Neurotech International Limited (ASX: NTI) (Neurotech or the Company) refers to its announcement released on 27 March 2019 with regards to Dr Adrian Attard Trevisan.

The Company clarifies that Dr Attard Trevisan has admitted that he does not have a PhD from University College London. Dr Attard Trevisan has been awarded a PhD from the University of Milan.

The Company's previous announcement incorrectly stated that Dr Attard Trevisan ceased to be an employee in April 2016. Dr Attard Trevisan ceased to be an employee in April 2017, as previously announced to ASX on 26 April 2017.

-ends-

About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech's primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the screening and treatment of symptoms associated with conditions such as autism.

Mente is the world's first home therapy that is clinically proven to increase engagement and improve relaxation in autistic children with elevated delta band brain activity.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

Media enquiries

Matthew Wright

matt@nwrcommunications.com.au

Tel: +61 451 896 420

Neurotech International Ltd

ABN 73 610 205 402

Level 14, 225 St Georges Terrace

Perth, Western Australia 6060

www.neurotechinternational.com